Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 12/2010

01-12-2010 | Original Research Paper

The effect of the expression of angiotensin II on extracellular matrix metalloproteinase inducer (EMMPRIN) in macrophages is mediated via the AT1/COX-2/PGE2 pathway

Authors: Li-xia Yang, Jin-shan Ye, Rui-wei Guo, Hong Liu, Xian-mei Wang, Feng Qi, Chuanming Guo

Published in: Inflammation Research | Issue 12/2010

Login to get access

Abstract

Aim

To explore the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) in THP-1 macrophages induced by angiotensin II (Ang II) and the mechanism of EMMPRIN expression.

Methods

THP-1 cells were cultured and induced into macrophages, then stimulated with 10−6 mol/L Ang II. Levels of EMMPRIN gene and its protein were measured by real-time polymerase chain reaction and western blotting. Prostaglandin E2 (PGE2) expression was assayed by enzyme-linked immunosorbent assay. Antagonists of the angiotensin type-1 receptor (AT1R) and angiotensin type-2 receptor (AT2R) were used to inhibit the effect of Ang II, and PGE2 added to detail the mechanism of Ang II-induced EMMPRIN expression.

Results

Ang II clearly induced the expression of EMMPRIN mRNA and protein in macrophages; this expression peaked at 12 h and declined after 24 h. The tendency of enhancement of the levels of cyclooxygenase-2 (COX-2) and PGE2 was coincident with EMMPRIN expression. AT1-receptor antagonists and COX-2 inhibitors inhibited the effect of Ang II, but AT2-receptor antagonists did not.

Conclusion

Ang II can up-regulate EMMPRIN expression in THP-1 macrophages via the AT1/COX-2/PGE2 signal transduction pathway, and the effect can be inhibited by losartan and NS-398.
Literature
1.
Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer. 2002;99:520–8.CrossRefPubMed
2.
Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55:434–9.PubMed
3.
Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B, et al. Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett. 1998;441:88–92.CrossRefPubMed
4.
Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res. 2003;1:420–7.PubMed
5.
Major T, Liang L, Lu X. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol. 2002;22:1200–7.CrossRefPubMed
6.
Yoon YW, Kwon HM, Hwang KC, Choi EY, Hong BK, Kim D, et al. Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis. 2005;180:37–44.CrossRefPubMed
7.
Hagemann T, Wilson J, Kulbe H. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005;175:1197–205.PubMed
8.
Abe N, Osanai T, Fujiwara T, Kameda K, Matsunaga T, Okumura K. C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. Life Sci. 2006;78:1021–8.CrossRefPubMed
9.
Schmidt R, Bultmann A, Ungerer M. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation. 2006;113:834–41.CrossRefPubMed
10.
11.
Eldika N, Yerra L, Chi DS, Krishnaswamy G. Atherosclerosis as an inflammatory disease: implications for therapy. Front Biosci. 2004;9:2764–77.CrossRefPubMed
12.
McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001;86:746–56.PubMed
13.
Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther. 2008;118:161–80.CrossRefPubMed
14.
Cipollone F, Fazia M, Mezzetti A. Novel determinants of plaque instability. J Thromb Haemost. 2005;3:1962–75.CrossRefPubMed
15.
Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol. 2004;24:246–55.CrossRefPubMed
16.
Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, et al. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol. 2002;507:177–84.PubMed
17.
Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104:921–7.CrossRefPubMed
18.
Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation. 2003;107:1479–85.CrossRefPubMed
19.
Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M, et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation. 2004;109:1482–8.CrossRefPubMed
20.
Yusuf S, Sleiht P, Pogue J. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–53.CrossRefPubMed
21.
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.CrossRefPubMed
22.
Fox K. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–7.CrossRefPubMed
23.
Schieffer B, Schieffer E, Hilfiker-Kleiner D. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372–8.PubMed
24.
Ohnaka K, Numaguchi K, Yamakawa T, Inagami T. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension. 2000;35:68–75.PubMed
25.
Brilla CG, Zhou G, Rupp H, Maisch B, Weber KT. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol. 1995;76:8D–13D.CrossRefPubMed
26.
Park EK, Jung HS, Yang HI, Yoo MC, Kim C, Kim KS. Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res. 2007;56:45–50.CrossRefPubMed
27.
Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586–93.PubMed
28.
Blessing E, Preusch M, Kranzhofer R, Kinscherf R, Marx N, Rosenfeld ME, et al. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis. 2008;199:295–303.CrossRefPubMed
29.
Ayabe N, Babaev VR, Tang Y, Tanizawa T, Fogo AB, Linton MF, et al. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Atherosclerosis. 2006;184:312–21.CrossRefPubMed
30.
Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605–12.CrossRefPubMed
31.
Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol. 2003;26:55–9.CrossRefPubMed
32.
Luchtefeld M, Grote K, Grothusen C, Bley S, Bandlow N, Selle T, et al. Angiotensin II induces MMP-2 in a p47phox-dependent manner. Biochem Biophys Res Commun. 2005;328:183–8.CrossRefPubMed
33.
Guo RW, Yang LX, Wang H, Liu B, Wang L. Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells. Regul Pept. 2008;147:37–44.CrossRefPubMed
34.
Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl. 1997;49:15–9.PubMed
35.
Hong BK, Kwon HM, Lee BK, Kim D, Kim IJ, Kang SM, et al. Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J. 2000;41:82–8.PubMed
36.
Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816–23.CrossRefPubMed
37.
Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 2005;39:443–52.CrossRefPubMed
38.
Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem. 1997;272:24–7.CrossRefPubMed
39.
Spinale FG, Coker ML, Heung LJ. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944–9.PubMed
40.
Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and matrix metalloproteinase activation in the failing heart: a potential therapeutic target. Circ Res. 2000;46:225–38.
41.
Brown DL, Desai KK, Vakili BA. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol. 2004;24:733–8.CrossRefPubMed
Metadata
Title
The effect of the expression of angiotensin II on extracellular matrix metalloproteinase inducer (EMMPRIN) in macrophages is mediated via the AT1/COX-2/PGE2 pathway
Authors
Li-xia Yang
Jin-shan Ye
Rui-wei Guo
Hong Liu
Xian-mei Wang
Feng Qi
Chuanming Guo
Publication date
01-12-2010
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 12/2010
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-010-0223-3

Other articles of this Issue 12/2010

Inflammation Research 12/2010 Go to the issue

Original Research Paper

The pentapeptide PLNPK inhibits systemic lupus erythematosus-associated renal damage

Original Research Paper

β1,4-Galactosyltransferase-I contributes to the inflammatory processes in synovial tissue of patients with rheumatoid arthritis

Original Research Paper

Rebamipide inhibits tumor necrosis factor-α-induced interleukin-8 expression by suppressing the NF-κB signal pathway in human umbilical vein endothelial cells

Original Research Paper

Exhaled 8-isoprostane in sarcoidosis: relation to superoxide anion production by bronchoalveolar lavage cells

Review

Helicobacter pylori: a ROS-inducing bacterial species in the stomach

Original Research Paper

Central and peripheral anti-inflammatory effects of maprotiline on carrageenan-induced paw edema in rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits